Cell Therapy Clinical Operations (Associate Director) - Immix Biopharma (Nasdaq: IMMX) : Job Details

Cell Therapy Clinical Operations (Associate Director)

Immix Biopharna, Inc (NASDAQ:IMMX)

Los Angeles, CA / Hybrid

Our 3 Core Values

• Intelligence
• Integrity
• Initiative

How You Will Contribute to Advancing Clinical Trials

As our Associate Director, Cell Therapy (CAR-T) Clinical Operations, you will be accountable for the day-to-day study management and successful delivery of one or more clinical trials in accordance with the protocol, Immix SOPs and good clinical practices (GCP) and applicable regulations. By managing all aspects of the study including study start-up, budget and timeline, you'll play a critical role in advancing our life-saving therapies through the clinic and to patients who need it most.

What You'll Do

• For our Cell therapy (CAR-T) programs: Oversee scope, quality, timelines, and budget for our early-stage clinical trial, working with internal functional leads, CRO, and vendors to ensure overall project objectives are met.
• Lead site and study management activities, including study start-up and development of critical study documents.
• Provide study-specific training and leadership to clinical research staff, including CRO, CRAs, sites and other contract personnel.
• Effectively communicate expectations to CRO, ensure appropriate site management, hold CRO accountable to timelines, and verify quality metrics.
• Anticipate obstacles or complex issues at the site, vendor, and study levels, and implements solutions.
• Proactively identify issues for escalation, participate in problem-solving and implementation of risk mitigation.
• Develop and ensure compliance with clinical monitoring plan; conducts or oversees co-monitor as needed for staff training and quality assurance (QA) purposes.
• Review the quality and integrity of the clinical data through review of electronic CRF data. Work with CRO/sites to resolve data queries.

Skills and Experience We Look For

• 3-5+ years of cell therapy clinical operations experience, including some experience with early phase research design.
• CRA experience at some point in career a plus.
• BA/BSc or higher (MD/PharmD/PhD) in natural or health sciences (biology, pharmacology, pharmaceutical sciences, or equivalent)
• Strong knowledge of clinical research process, including working knowledge of all functional areas of clinical trials and regulatory requirements.
• Exceptional project management skills, organizational and problem-solving skills
• Eager to learn with a collaborative, team-oriented mindset.
• Excellent written and verbal communication skills with an ability to express complex ideas to study personnel at research and clinical institutions.

Rewards at Immix

Our people are our greatest asset, and supporting their well-being is an essential part of delivering on our mission and impacting the lives of patients. Putting this belief into practice means offering strong compensation and benefits.

Compensation will be commensurate with experience. Our compensation package also includes an annual bonus based on company goals and an equity grant. Our benefits package includes: coverage for medical, dental and vision for team members and dependents and 401k.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b/2 trial NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated no neurotoxicity of any kind in AL Amyloidosis and short duration of cytokine release syndrome (CRS), supporting expansion into select immune-mediated diseases. NXC-201 has been awarded Orphan Drug Designation (ODD) in AL Amyloidosis by the US FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.